Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents.

Compound lipophilicity is a fundamental physicochemical property that plays a pivotal role in the absorption, distribution, metabolism, and elimination (ADME) of therapeutic drugs. Lipophilicity is expressed in several different ways, including terms such as Log P, clogP, delta Log P, and Log D. Often a parabolic relationship exists between measured lipophilicity and in vivo brain penetration of drugs, where those moderate in lipophilicity often exhibit highest uptake. Reduced brain extraction of more lipophilic compounds is associated with increased non-specific binding to plasma proteins. More lipophilic compounds can also be more vulnerable to P450 metabolism, leading to faster clearance. Very polar compounds normally exhibit high water solubility, fast clearance through the kidneys, and often contain ionizable functional groups that limit blood-brain barrier (BBB) penetration. The brain penetration and specific to non-specific binding ratios exhibited in vivo by positron emission tomography (PET) and single photon emission computed tomography (SPECT) radiotracers involves a complex interplay between many critical factors, including lipophilicity, receptor affinity, metabolism, molecular size and shape, ionization potential, and specific binding to BBB efflux pumps or binding sites on albumin or other plasma proteins. This paper explores situations in which lipophilicity is a good predictor of BBB penetration, as well as those where this correlation is poor. The more commonly used methods for measuring lipophilicity are presented, and the various terms often found in the literature outlined. An attempt is made to describe how this information can be used in optimizing the development of PET and SPECT tracers that target the central nervous system (CNS).

[1]  J. Trojanowski,et al.  IBOX(2-(4'-dimethylaminophenyl)-6-iodobenzoxazole): a ligand for imaging amyloid plaques in the brain. , 2001, Nuclear Medicine and Biology.

[2]  A. Alavi,et al.  Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  Biodistribution and radiation dosimetry of radioiodinated-SCH 23982, a potential dopamine D-1 receptor imaging agent. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  M. Roberts,et al.  Experimental methods for studying drug uptake in the head and brain. , 2000, Current drug metabolism.

[5]  M. Kilberg,et al.  Molecular biology of mammalian amino acid transporters. , 1996, Annual review of biochemistry.

[6]  R. Kessler,et al.  (S)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-[125I]iodo- 2-methoxybenzamide hydrochloride, a new selective radioligand for dopamine D-2 receptors. , 1988, Journal of medicinal chemistry.

[7]  Kengo Ito,et al.  Synthesis and preliminary evaluation of [11C]NE-100 labeled in two different positions as a PET sigma receptor ligand. , 1998, Nuclear medicine and biology.

[8]  Betz Al,et al.  Epithelial properties of brain capillary endothelium. , 1985 .

[9]  D. Begley,et al.  The Blood‐brain Barrier: Principles for Targeting Peptides and Drugs to the Central Nervous System , 1996, The Journal of pharmacy and pharmacology.

[10]  H. Tanaka,et al.  Drug-protein binding and blood-brain barrier permeability. , 1999, The Journal of pharmacology and experimental therapeutics.

[11]  D Mackay,et al.  A novel method for measuring membrane-water partition coefficients of hydrophobic organic chemicals: comparison with 1-octanol-water partitioning. , 1988, Journal of Pharmacy and Science.

[12]  J. Mukherjee,et al.  Development of N-[3-(2',4'-dichlorophenoxy)-2-18F-fluoropropyl]-N-methylpropargylamine (18F-fluoroclorgyline) as a potential PET radiotracer for monoamine oxidase-A. , 1999, Nuclear medicine and biology.

[13]  R. Kaliszan,et al.  Lipophilicity and pKa estimates from gradient high-performance liquid chromatography. , 2002, Journal of chromatography. A.

[14]  C. Crouzel,et al.  High specific radioactivity (1R,2S)-4-[(18)F]fluorometaraminol: a PET radiotracer for mapping sympathetic nerves of the heart. , 2000, Nuclear medicine and biology.

[15]  P D Leeson,et al.  Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists. , 1997, Journal of medicinal chemistry.

[16]  R. Pleus,et al.  Synthesis of (+/-)-[18F]BMY 14802, its enantiomers and their anatomical distributions in rodents. , 1993, Nuclear medicine and biology.

[17]  David F. V. Lewis,et al.  Baseline Lipophilicity Relationships in Human Cytochromes P450 Associated with Drug Metabolism , 2003, Drug metabolism reviews.

[18]  N. Nelson,et al.  Structure, function and brain localization of neurotransmitter transporters. , 1994, The Journal of experimental biology.

[19]  D. Jewett,et al.  (R)‐N‐[11C]methyl‐3‐pyrrolidyl benzilate, a high‐affinity reversible radioligand for PET studies of the muscarinic acetylcholine receptor , 2002, Synapse.

[20]  O. Schober,et al.  Preparation of 8-[3-(4-fluorobenzoyl)-propyl]-1-(4-[123I] iodobenzoyl)-1,3,8-triazaspiro[4,5]decan-4-one: a novel selective serotonin 5-HT2 receptor agent. , 1997, Nuclear medicine and biology.

[21]  G R Wilkinson,et al.  Plasma binding and transport of diazepam across the blood-brain barrier. No evidence for in vivo enhanced dissociation. , 1989, The Journal of clinical investigation.

[22]  P. Herscovitch,et al.  In vivo muscarinic binding of 3‐(alkylthio)‐3‐thiadiazolyl tetrahydropyridines , 1999, Synapse.

[23]  H. Onoe,et al.  In vitro and in vivo characterization of (+)-3-[11C]cyano-dizocilpine , 1998, Journal of Neural Transmission.

[24]  Lipophilicity and biological acitivity. Drug transport and drug distribution in model systems and in biological systems. , 1979, Arzneimittel-Forschung.

[25]  Manfred Kansy,et al.  Predicting plasma protein binding of drugs: a new approach. , 2002, Biochemical pharmacology.

[26]  Bernard Testa,et al.  Lipophilicity in Molecular Modeling , 1996, Pharmaceutical Research.

[27]  M. Abraham,et al.  Rapid-gradient HPLC method for measuring drug interactions with immobilized artificial membrane: comparison with other lipophilicity measures. , 2000, Journal of pharmaceutical sciences.

[28]  R. Dannals,et al.  5-[I-125/123]lodo-3(2(S)-azetidinylmethoxy)pyridine, a radioiodinated analog of A-85380 for in vivo studies of central nicotinic acetylcholine receptors. , 1998, Life sciences.

[29]  L. Reneman,et al.  [123I]FP-CIT binding in rat brain after acute and sub-chronic administration of dopaminergic medication , 2000, European Journal of Nuclear Medicine.

[30]  D. Greenblatt,et al.  In vitro quantitation of benzodiazepine lipophilicity: relation to in vivo distribution. , 1983, British journal of anaesthesia.

[31]  J. Mcculloch,et al.  Synthesis and binding characteristics of N-(1-naphthyl)-N'-(3-[(125)I]-iodophenyl)-N'-methylguanidine ([(125)I]-CNS 1261): a potential SPECT agent for imaging NMDA receptor activation. , 2000, Nuclear medicine and biology.

[32]  S. Yalkowsky,et al.  Solubility and partitioning VI: octanol solubility and octanol-water partition coefficients. , 1983, Journal of pharmaceutical sciences.

[33]  Relative hydrophobicity of organic compounds measured by partitioning in aqueous two-phase systems. , 2000, Journal of chromatography. B, Biomedical sciences and applications.

[34]  T. D. Paulis,et al.  The Discovery of Epidepride and Its Analogs as High-Affinity Radioligands for Imaging Extrastriatal Dopamine D2 Receptors in Human Brain , 2003 .

[35]  Stephen A. Wring,et al.  Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs , 2002, Journal of Pharmacology and Experimental Therapeutics.

[36]  M. Kilberg,et al.  Recent advances in mammalian amino acid transport. , 1993, Annual review of nutrition.

[37]  Patrick Poulin,et al.  Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. , 2002, Journal of pharmaceutical sciences.

[38]  J. Korf,et al.  Synthesis and organ distribution of [18F]fluoro-Org 6141 in the rat: a potential glucocorticoid receptor ligand for positron emission tomography. , 1995, Nuclear medicine and biology.

[39]  B. Kanner,et al.  Glutamate transporters from brain , 1993, FEBS letters.

[40]  Sylvain Houle,et al.  In vitro and in vivo characterisation of [11C]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography. , 2002, Nuclear medicine and biology.

[41]  C. Shiue,et al.  Comparative PET studies of the distribution of (-)-3,4-methylenedioxy-N-[11C]methamphetamine and (-)-[11C]methamphetamine in a monkey brain. , 1995, Nuclear medicine and biology.

[42]  J. Holden,et al.  Synthesis and preliminary evaluation of 18F-labeled 4-thia palmitate as a PET tracer of myocardial fatty acid oxidation , 2000 .

[43]  M. Danhof,et al.  Drug transport across the blood-brain barrier , 1992, Pharmaceutisch Weekblad.

[44]  M. Welch,et al.  Oxohexestrol derivatives labeled with fluorine-18. Synthesis, receptor binding and in vivo distribution of two non-steroidal estrogens as potential breast tumor imaging agents. , 1994, Nuclear medicine and biology.

[45]  S. Kushner,et al.  Specificity of diastereomers of [99mTc]TRODAT-1 as dopamine transporter imaging agents. , 1998, Journal of medicinal chemistry.

[46]  Martin P. Payne,et al.  COMPARISON OF MODELS FOR THE ESTIMATION OF BIOLOGICAL PARTITION COEFFICIENTS , 2002, Journal of toxicology and environmental health. Part A.

[47]  M. Welch,et al.  Radiosynthesis, in vitro validation, and in vivo evaluation of 18F-labeled COX-1 and COX-2 inhibitors. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[48]  S. Houle,et al.  Characterization of r-[11C]rolipram for PET imaging of phosphodieterase-4: in vivo binding, metabolism, and dosimetry studies in rats. , 2001, Nuclear medicine and biology.

[49]  D. Kuhl,et al.  [18F]fluoroethoxy‐benzovesamicol, a PET radiotracer for the vesicular acetylcholine transporter and cholinergic synapses , 1998, Synapse.

[50]  H. Minn,et al.  Blood metabolism of [methyl-11C]choline; implications for in vivo imaging with positron emission tomography , 2000, European Journal of Nuclear Medicine.

[51]  M. Welch,et al.  Synthesis and evaluation of two positron-labeled nitric oxide synthase inhibitors, S-[11C]methylisothiourea and S-(2-[18F]fluoroethyl)isothiourea, as potential positron emission tomography tracers. , 1996, Journal of medicinal chemistry.

[52]  K. Dill,et al.  Solute partitioning into lipid bilayer membranes. , 1988, Biochemistry.

[53]  H. Kung,et al.  Neutral and stereospecific Tc-99m complexes: [99mTc]N-benzyl-3,4-di-(N-2-mercaptoethyl)-amino-pyrrolidines (P-BAT). , 1999, Nuclear medicine and biology.

[54]  B. Christian,et al.  Radiosynthesis and in vitro evaluation of 2-(N-alkyl-N-1'-11C-propyl)amino-5-hydroxytetralin analogs as high affinity agonists for dopamine D-2 receptors. , 1999, Nuclear medicine and biology.

[55]  B. Testa,et al.  Determination of Lipophilicity and Hydrogen‐bond Donor Acidity of Bioactive Sulphonyl‐containing Compounds by Reversed‐phase HPLC and Centrifugal Partition Chromatography and their Application to Structure‐activity Relations , 1991, The Journal of pharmacy and pharmacology.

[56]  M. Kilbourn,et al.  The role of species-dependent metabolism in the regional brain retention of 18F-labeled muscarinic acetylcholine receptor ligands. , 2001, Nuclear medicine and biology.

[57]  B. Zeeberg,et al.  In vitro and in vivo m2 muscarinic subtype selectivity of some dibenzodiazepinones and pyridobenzodiazepinones , 2000, Brain Research.

[58]  P. Schubiger,et al.  123I-labeling and evaluation of Ro 43-0463, a SPET tracer for MAO-B imaging. , 1995, Nuclear medicine and biology.

[59]  A. Lázníčková,et al.  The effect of lipophilicity on the protein binding and blood cell uptake of some acidic drugs. , 1995, Journal of pharmaceutical and biomedical analysis.

[60]  D. Siluk,et al.  Chromatographic retention parameters in medicinal chemistry and molecular pharmacology. , 2003, Current medicinal chemistry.

[61]  T. Conway,et al.  Synthesis and preliminary evaluation of (S)-(2-[18F]fluoro-4,5-dihydroxyphenyl)-2-methyl L-alanine, (S)-[18F]-FMEDOPA, a potentially improved imaging agent for the presynaptic dopaminergic nervous system. , 1996, Nuclear medicine and biology.

[62]  S. Stone-Elander,et al.  In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants. , 1999, Life sciences.

[63]  Han van de Waterbeemd,et al.  Substructure and whole molecule approaches for calculating log P , 2001, J. Comput. Aided Mol. Des..

[64]  W. J. Lambert,et al.  Development of a Preformulation Lipophilicity Screen Utilizing a C-18-Derivatized Polystyrene-Divinylbenzene High-Performance Liquid Chromatographic (HPLC) Column , 1990, Pharmaceutical Research.

[65]  J. Lin,et al.  Effects of protein binding and experimental disease states on brain uptake of benzodiazepines in rats. , 1990, The Journal of pharmacology and experimental therapeutics.

[66]  L. Aarons,et al.  Quantitative Structure-Pharmacokinetics Relationships: I. Development of a Whole-Body Physiologically Based Model to Characterize Changes in Pharmacokinetics Across a Homologous Series of Barbiturates in the Rat , 1997, Journal of Pharmacokinetics and Biopharmaceutics.

[67]  Rikki N. Waterhouse,et al.  Halogenated 4-(phenoxymethyl)piperidines as potential radiolabeled probes for σ-1 receptors : In vivo evaluation of [123I]-1-(iodopropen-2-yl)-4-[(4-cyanophenoxy)methyl]piperidine , 1997 .

[68]  J. Tillement,et al.  Drug transfer across the blood‐brain barrier and improvement of brain delivery , 1999, Fundamental & clinical pharmacology.

[69]  R. Pignatello,et al.  Lipophilicity evaluation by RP-HPLC of two homologous series of methotrexate derivatives. , 2000, Pharmaceutica Acta Helvetiae.

[70]  H. Kubinyi Nonlinear dependence of biological activity on hydrophobic character: the bilinear model. , 1979, Il Farmaco; edizione scientifica.

[71]  P. Dessen,et al.  Drug-binding properties of rat alpha 1-foetoprotein. Binding of warfarin, phenylbutazone, azapropazone, diazepam, digitoxin and cholic acid. , 1984, Biochemical Journal.

[72]  Han van de Waterbeemd,et al.  Lipophilicity in PK design: methyl, ethyl, futile , 2001, J. Comput. Aided Mol. Des..

[73]  D. Scherman,et al.  High lipophilicity decreases drug transport across intestinal epithelial cells. , 1994, The Journal of pharmacology and experimental therapeutics.

[74]  M. Raichle,et al.  Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[75]  B. Testa,et al.  Physicochemical profiling in drug research: a brief survey of the state-of-the-art of experimental techniques , 2002, Cellular and Molecular Life Sciences CMLS.

[76]  Hartwig Wolburg,et al.  Tight junctions of the blood-brain barrier: development, composition and regulation. , 2002, Vascular pharmacology.

[77]  Alan A. Wilson,et al.  An admonition when measuring the lipophilicity of radiotracers using counting techniques. , 2001, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[78]  M. Laruelle,et al.  In vivo evaluation of [11C]-3-[2-[(3-methoxyphenylamino)carbonyl]ethenyl]-4,6-dichloroindole-2-carboxylic acid ([11C]3MPICA) as a PET radiotracer for the glycine site of the NMDA ion channel. , 2002, Nuclear medicine and biology.

[79]  Alan A. Wilson,et al.  Comparative Evaluation in Nonhuman Primates of Five PET Radiotracers for Imaging the Serotonin Transporters: [11C]McN 5652, [11C]ADAM, [11C]DASB, [11C]DAPA, and [11C]AFM , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[80]  D. Wong,et al.  Synthesis of an I-123 analog of A-85380 and preliminary SPECT imaging of nicotinic receptors in baboon. , 1999, Nuclear medicine and biology.

[81]  J. Viña,et al.  The Complementary Membranes Forming the Blood‐Brain Barrier , 2002, IUBMB life.

[82]  M. Laruelle,et al.  Simplified multidose preparation of iodine-123-beta-CIT: a marker for dopamine transporters. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[83]  R. Mach,et al.  Synthesis and biological characterization of stable and radioiodinated (+/-)-trans-2-hydroxy-3-P[4-(3-iodophenyl)piperidyl]-1,2,3,4-tetrahydronaphthalene (3'-IBVM). , 2000, Nuclear medicine and biology.

[84]  A. Lammertsma,et al.  Development of central 5-HT2A receptor radioligands for PET: comparison of [3H]RP 62203 and [3H]SR 46349B kinetics in rat brain. , 1996, Nuclear medicine and biology.

[85]  H. Matsuda,et al.  Radioiodinated (—)-2-[4-(3‐iodophenyl) piperidino] cyclohexanol: A potential radioligand for mapping presynaptic cholinergic neurons , 1996, Nuclear medicine communications.

[86]  Peter L. Bonate,et al.  Animal models for studying transport across the blood-brain barrier , 1995, Journal of Neuroscience Methods.

[87]  R. G. Manning,et al.  Evaluation of 5‐[18F]Fluoropropylepidepride as a potential pet radioligand for imaging dopamine D2 receptors , 1993, Synapse.

[88]  M. Senda,et al.  Synthesis and preliminary evaluation of a carbon-11-labeled adenosine transporter blocker [11C]KF21652 , 2001 .

[89]  Y. Magata,et al.  Evaluation of N-alkyl derivatives of radioiodinated spiperone as radioligands for in vivo dopamine D2 receptor studies: effects of lipophilicity and receptor affinity on the in vivo biodistribution. , 1992, Chemical & pharmaceutical bulletin.

[90]  Determination of octanol‐water partition coefficients for carbonate esters and other small organic molecules by microemulsion electrokinetic chromatography , 2003, Electrophoresis.

[91]  R. Lew,et al.  N-(6-18F-fluorohexyl)-N-methylpropargylamine: a fluorine-18-labeled monoamine oxidase B inhibitor for potential use in PET studies. , 1999, Nuclear medicine and biology.

[92]  M. K. Das,et al.  Fluorinated benzamide neuroleptics--III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. , 1995, Nuclear medicine and biology.

[93]  R. Rogers,et al.  Partitioning of small organic molecules in aqueous biphasic systems. , 1998, Journal of chromatography. B, Biomedical sciences and applications.

[94]  K. Taguchi,et al.  Synthesis and evaluation of radiolabeled piperazine derivatives of vesamicol as SPECT agents for cholinergic neurons. , 2001, Nuclear medicine and biology.

[95]  J. Baron,et al.  Specific in vivo binding in the rat brain of [18F]RP 62203: a selective 5-HT2A receptor radioligand for positron emission tomography. , 1996, Nuclear medicine and biology.

[96]  J. Bading,et al.  Blocking catabolism with eniluracil enhances PET studies of 5-[18F]fluorouracil pharmacokinetics. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[97]  J R Chretien,et al.  Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. , 1998, Journal of drug targeting.

[98]  G Folkers,et al.  Review of theoretical passive drug absorption models: historical background, recent developments and limitations. , 1996, Pharmaceutica acta Helvetiae.

[99]  Alex Avdeef,et al.  Physicochemical Profiling (Solubility, Permeability and Charge State) , 2001 .

[100]  H. M. Solomon,et al.  A rapid method for the estimation of drug‐albumin affinity constants in human plasma , 1971, Clinical pharmacology and therapeutics.

[101]  M. Welch,et al.  11 beta-methoxy-, 11 beta-ethyl- and 17 alpha-ethynyl-substituted 16 alpha-fluoroestradiols: receptor-based imaging agents with enhanced uptake efficiency and selectivity. , 1990, Journal of medicinal chemistry.

[102]  M. Hediger,et al.  Introduction: glutamate transport, metabolism, and physiological responses. , 1999, The American journal of physiology.

[103]  M. Goodman,et al.  In vivo evaluation of [123I]-8-[4-[2-(5-iodothienyl)]-4-oxobutyl]-3-methyl-1-phenyl-1,3 ,8-tri azaspiro[4.5]decan-4-one as a potential dopamine D2 receptor radioligand for SPECT. , 1998, Nuclear medicine and biology.

[104]  Mark E. Schmidt,et al.  Evaluation of [3H]LY341495 for labeling group II metabotropic glutamate receptors in vivo. , 2003, Nuclear medicine and biology.

[105]  M. Kassiou,et al.  Pharmacological evaluation of (S)-8-[123I]iodobretazenil: a radioligand for in vivo studies of central benzodiazepine receptors. , 2003, Nuclear medicine and biology.

[106]  S. Ametamey,et al.  SYNTHESIS AND IN VITRO AND IN VIVO EVALUATION OF [11C]METHYL-BIII277CL FOR IMAGING THE PCP-BINDING SITE OF THE NMDA RECEPTOR BY PET , 2002, Journal of receptor and signal transduction research.

[107]  R. Bendayan,et al.  Functional expression and localization of P‐glycoprotein at the blood brain barrier , 2002, Microscopy research and technique.

[108]  R. Waterhouse,et al.  In vivo evaluation of [18F]1-(3-fluoropropyl)-4-(4-cyanophenoxymethyl)piperidine: a selective sigma-1 receptor radioligand for PET. , 1997, Nuclear medicine and biology.

[109]  M. Otagiri,et al.  Species Differences of Serum Albumins: I. Drug Binding Sites , 1997, Pharmaceutical Research.

[110]  André Luxen,et al.  Effect of endogenous serotonin on the binding of the 5‐HT1A PET ligand 18F‐MPPF in the rat hippocampus: kinetic β measurements combined with microdialysis , 2002, Journal of neurochemistry.

[111]  B. Shroot,et al.  Determination of partition coefficients of glucocorticosteroids by high-performance liquid chromatography. , 1984, Journal of pharmaceutical sciences.

[112]  N. Guo,et al.  Pharmacokinetics and brain distribution in non human primate of R(-)[123I]DOI, A 5HT(2A/2C) serotonin agonist. , 2002, Nuclear medicine and biology.

[113]  A. Horti,et al.  Synthesis and evaluation of a novel series of 2-chloro-5-((1-methyl-2-(S)-pyrrolidinyl)methoxy)-3-(2-(4-pyridinyl)vinyl)pyridine analogues as potential positron emission tomography imaging agents for nicotinic acetylcholine receptors. , 2002, Journal of medicinal chemistry.

[114]  G R Wilkinson,et al.  Brain uptake of benzodiazepines: effects of lipophilicity and plasma protein binding. , 1988, The Journal of pharmacology and experimental therapeutics.

[115]  M. Kiyosawa,et al.  Carbon-11-labeled KF21213: a highly selective ligand for mapping CNS adenosine A(2A) receptors with positron emission tomography. , 2000, Nuclear medicine and biology.

[116]  D. Rockey,et al.  Preliminary evaluation of 15-[18F]fluoro-3-oxa-pentadecanoate as a PET tracer of hepatic fatty acid oxidation. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[117]  M. Welch,et al.  Biodistribution of N-alkyl and N-fluoroalkyl derivatives of spiroperidol; radiopharmaceuticals for PET studies of dopamine receptors. , 1986, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[118]  T. Suhara,et al.  Synthesis, in vitro and in vivo pharmacology of a C-11 labeled analog of CP-101,606, (+/-)threo-1-(4-hydroxyphenyl)-2-[4-hydroxy-4-(p-[11C]methoxyphenyl)piperidino]-1-propanol, as a PET tracer for NR2B subunit-containing NMDA receptors. , 2002, Nuclear medicine and biology.

[119]  H. Minn,et al.  Pharmacokinetics of [18F]FETNIM: A Potential Hypoxia Marker for PET , 2001 .

[120]  U. Kragh-Hansen,et al.  Evidence for a large and flexible region of human serum albumin possessing high affinity binding sites for salicylate, warfarin, and other ligands. , 1988, Molecular pharmacology.

[121]  P. Ruelle The n-octanol and n-hexane/water partition coefficient of environmentally relevant chemicals predicted from the mobile order and disorder (MOD) thermodynamics. , 2000, Chemosphere.

[122]  P. Carnochan,et al.  Radiolabelled 5'-iodo-2'-deoxyuridine: a promising alternative to [18F]-2-fluoro-2-deoxy-D-glucose for PET studies of early response to anticancer treatment. , 1999, Nuclear medicine and biology.

[123]  M. Palkovits,et al.  Localization and Dynamic Regulation of Biogenic Amine Transporters in the Mammalian Central Nervous System , 1998, Frontiers in Neuroendocrinology.

[124]  A. Tsantili-Kakoulidou,et al.  Synthesis, lipophilicity and biological evaluation of indole-containing derivatives of 1,3,4-thiadiazole and 1,2, 4-triazole. , 1998, Farmaco.

[125]  D. Drayer Lipophilicity, Hydrophilicity, and the Central Nervous System Side Effects of Beta Blockers , 1987, Pharmacotherapy.

[126]  Benjamin Ehrenberg,et al.  Do Liposome-binding Constants of Porphyrins Correlate with Their Measured and Predicted Partitioning Between Octanol and Water?¶ , 2002, Photochemistry and photobiology.

[127]  C. Dence,et al.  Synthesis, in vivo evaluation and PET study of a carbon-11-labeled neuronal nitric oxide synthase (nNOS) inhibitor S-methyl-L-thiocitrulline. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[128]  S. Yalkowsky,et al.  Solubility and partitioning IV: Aqueous solubility and octanol-water partition coefficients of liquid nonelectrolytes. , 1981, Journal of pharmaceutical sciences.

[129]  D. Charney,et al.  Comparison of [123I]ß-CIT and [123I]IPCIT as single-photon emission tomography radiotracers for the dopamine transporter in nonhuman primates , 2005, European Journal of Nuclear Medicine.

[130]  Synthesis and evaluation of racemic [(11)C]NS2456 and enantiomers as selective serotonin reuptake radiotracers for PET. , 2001, Nuclear medicine and biology.